Aubrey Rankin is Director of Revance Therapeutics, Inc.. Currently has a direct ownership of 94,091 shares of RVNC, which is worth approximately $241,813. The most recent transaction as insider was on Mar 15, 2022, when has been sold 1,372 shares (Common Stock) at a price of $15.79 per share, resulting in proceeds of $21,664. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 94.1K
0% 3M change
0% 12M change
Total Value Held $241,813

Aubrey Rankin Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 15 2022
SELL
Payment of exercise price or tax liability
$21,664 $15.79 p/Share
1,372 Reduced 1.44%
94,091 Common Stock
Dec 03 2021
BUY
Open market or private purchase
$432,900 $14.43 p/Share
30,000 Added 23.91%
95,463 Common Stock
Aug 16 2021
SELL
Open market or private sale
$246,648 $26.34 p/Share
9,364 Reduced 12.51%
65,463 Common Stock
Aug 15 2021
SELL
Payment of exercise price or tax liability
$128,773 $26.02 p/Share
4,949 Reduced 6.2%
74,827 Common Stock
Feb 02 2021
BUY
Grant, award, or other acquisition
-
11,905 Added 12.99%
79,776 Common Stock
AR

Aubrey Rankin

Director
Nashville, TN

Track Institutional and Insider Activities on RVNC

Follow Revance Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RVNC shares.

Notify only if

Insider Trading

Get notified when an Revance Therapeutics, Inc. insider buys or sells RVNC shares.

Notify only if

News

Receive news related to Revance Therapeutics, Inc.

Track Activities on RVNC